CT-95 for Advanced Cancers with Mesothelin Expression
This study is testing a new drug called CT-95 in people with advanced cancers that have a specific marker called mesothelin. These cancers include certain types of ovarian cancer, mesothelioma, and pancreatic cancer. CT-95 is a bispecific antibody, which is a type of medicine designed to target specific cells. The main goals are to find a safe dose of CT-95 and to see how often side effects occur. You might be able to join if you are 18 or older, have good general health, and your cancer has mesothelin. The study is currently unclear about its recruitment status and plans to enroll about 70 people.
- Study design
- This is a Phase 1a/1b, first-in-human, open-label study. It is designed to test different doses of CT-95 in approximately 70 participants.
- What's involved
- Participants will receive CT-95 intravenously once a week over a 4-week cycle. Treatment continues until the disease gets worse, side effects are too severe, or you or your doctor decide to stop.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be monitored for approximately 6 months after the first dose or until treatment stops, whichever comes first.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CT-95 in Advanced Cancers Associated With Mesothelin Expression
At a glance
Conditions
Where it's being run
9 sites across 7 statesStudy leadership
- Karen Chagin, MD · STUDY_DIRECTOR · Context Therapeutics Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Determine the MTD or RD of CT-95 [Safety and Tolerability]From date of first dose of CT-95 until 28 days following the first dose.
The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
The frequency and severity of adverse events, serious adverse events, and adverse events of special interest will be analyzed.